Breaking
Friday, June 19, 2026

Mergers & Acquisitions

🌏 NMPA

NMPA news and analysis for pharmaceutical BD, investment, and market access

Track global pharma M&A deals, divestitures, and partnerships. Gain critical intelligence for strategic investment and business development in life sciences.

Showing 1–10 of 10 articles

Quick answer

NovaPharmaNews Mergers & Acquisitions hub for NMPA covers 10 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.

High impact NewsJun 7, 2026

Fosun Pharma and AriBio Forge Alzheimer's Option Agreement: Deal Intelligence

FDA · Alzheimer's · 8 min

Dr. Yuki Tanaka
High impact NewsJun 3, 2026

Big Pharma's China Oncology Trials: Navigating a Landscape of Reduced Scrutiny

FDA · oncology · 5 min

Dr. Yuki Tanaka
High impact NewsJun 3, 2026

Kissei Pharmaceutical Halts Tavneos Use Amid Deaths

FDA · 6 min

Dr. Yuki Tanaka
High impact AnalysisJun 3, 2026

Injectable Drug Delivery Market Set for Significant Growth: Insights for Pharma Stakeholders

7 min

Dr. Yuki Tanaka
High impact AnalysisJun 2, 2026

Minghui and Qilu Pharmaceutical Unveil Promising MHB088C Data in mCRPC at ASCO 2026

mCRPC · 8 min

Dr. Yuki Tanaka
Critical impact NewsJun 2, 2026

BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors

FDA · 6 min

Dr. Yuki Tanaka
Critical impact NewsMay 4, 2026

Sun Pharma Organon Partnership to Expand Access to Key Medicines

women's health, spasticity, rheumatoid arthritis · 6 min

Dr. Yuna Park
Critical impact NewsMay 4, 2026

UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases

Autoimmune and inflammatory diseases · 3 min

Kenji Watanabe
High impact NewsApr 28, 2026

IMG Pharma Acquires Matsumoto Pharmaceutical in Strategic Japanese Market Expansion Deal

2 min

Kenji Watanabe
Critical impact NewsApr 28, 2026

BioMarin Completes $3 Billion Acquisition of Amicus Therapeutics, Expands Rare Disease Portfolio with Galafold and Pompe Therapies

Rare genetic diseases (lysosomal storage disorders) · 3 min

Dr. Yuna Park

Frequently asked questions

How often is this topic updated?

New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.

Where does this coverage come from?

Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.